Nanovibronix (FEED) Stock Price, News & Analysis

Company Overview

NanoVibronix, Inc. is a medical device company focused on developing and commercializing noninvasive therapeutic ultrasound products. Its technology is designed to deliver low-intensity ultrasound through the skin for applications involving pain management, wound care and other therapeutic needs.

The company’s product portfolio has included PainShield, a wearable ultrasound device intended to provide localized relief for chronic and acute pain, and WoundShield, a device designed to support the treatment of chronic and difficult-to-heal wounds. NanoVibronix has marketed its products through healthcare providers, distributors and direct-to-consumer channels.

NanoVibronix has operated in the United States and international markets, including through distribution relationships in Europe and other regions. Public references generally identify NanoVibronix under the ticker symbol NAOV; the symbol FEED does not appear to correspond to the company.

Key Stats

• Today's Range: $0.21 to $0.30
• 50-Day Range: $0.22 to $4.31
• 52-Week Range: $0.12 to $73.08
• Volume: 13,745 shs
• Average Volume: 348,518 shs
• Market Capitalization: $258.72 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nanovibronix Stock Analysis - MarketRank™

Nanovibronix scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Nanovibronix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nanovibronix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nanovibronix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nanovibronix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nanovibronix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FEED.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanovibronix does not currently pay a dividend.

Dividend Growth

Nanovibronix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for FEED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanovibronix insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of Nanovibronix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.39% of the stock of Nanovibronix is held by institutions.

Company Calendar

• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:FEED
• CIK: 1326706
• Web: nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($117.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.18 million
• Net Margins: -1,093.61%
• Pretax Margin: -1,111.94%
• Return on Equity: -60.73%
• Return on Assets: -48.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $365.43 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 924,000
• Free Float: 810,000
• Market Cap: $258.72 thousand
• Optionable: N/A
• Beta: 1.60